Clinical characteristics of patients studied 19-23 days after transplantation
| . | Donors . | Total, n = 51 . | ||
|---|---|---|---|---|
| HLA-identical sibling, n = 16 . | HLA-matched unrelated, n = 20* . | HLA-mismatched unrelated, n = 15 . | ||
| BMT/PBSCT recipients | 12/4 | 19/1 | 15/0 | 46/5 |
| Age, years | 21-59 | 26-55 | 19-49 | 19-59 |
| Median years | 46 | 38 | 36 | 39 |
| Maximum acute GVHD | ||||
| Grade 0/I | 5/1 | 2/0 | 0/0 | 7/1 |
| Grade II-IV† | 10 | 8 | 12 | 30 |
| Patients treated for acute GVHD prior to analysis of apoptosis‡ | 0 | 10 | 3 | 13 |
| . | Donors . | Total, n = 51 . | ||
|---|---|---|---|---|
| HLA-identical sibling, n = 16 . | HLA-matched unrelated, n = 20* . | HLA-mismatched unrelated, n = 15 . | ||
| BMT/PBSCT recipients | 12/4 | 19/1 | 15/0 | 46/5 |
| Age, years | 21-59 | 26-55 | 19-49 | 19-59 |
| Median years | 46 | 38 | 36 | 39 |
| Maximum acute GVHD | ||||
| Grade 0/I | 5/1 | 2/0 | 0/0 | 7/1 |
| Grade II-IV† | 10 | 8 | 12 | 30 |
| Patients treated for acute GVHD prior to analysis of apoptosis‡ | 0 | 10 | 3 | 13 |
Statistics are given for recipients of bone marrow transplantation/peripheral blood stem cell transplantation (BMT/PBSCT). The median day of study after transplantation was day 21 for all donor types.
HLA-matched unrelated donors were studied 20-23 days after transplantation.
At the time of study, 18 patients had grade II-IV clinical acute GVHD, and 12 patients developed acute GVHD within 24-72 days following transplantation (median, 30 days). All patients in this group were studied prior to receiving systemic glucocorticosteroids.
A total of 13 patients received systemic glucocorticosteroids for treatment of acute GVHD prior to analysis of apoptosis.